A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.
about
Adverse effects of antiretroviral therapy for HIV infectionMetabolic effects of indinavir in healthy HIV-seronegative menBiological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaquesBody composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors.A prospective, observational cohort study to elicit adverse effects of antiretroviral agents in a remote resource-restricted tribal population of Chhattisgarh.Dyslipidemia and adherence to the Mediterranean diet in Croatian HIV-infected patients during the first year of highly active antiretroviral therapy.Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi MetropolisStudy of Body Composition and Metabolic Parameters in HIV-1 Male Patients.Antiretroviral treatment associated hyperglycemia and dyslipidemia among HIV infected patients at Burayu Health Center, Addis Ababa, Ethiopia: a cross-sectional comparative study.HIV-1 protease inhibitors.Coronary artery disease and human immunodeficiency virus infection.Disorders of glucose metabolism in patients infected with human immunodeficiency virus.Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism.Glucose disorders associated with HIV and its drug therapy.Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors.Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern IndiaNRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: fact or fiction?Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders?Nutrition and HIV infection.Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.Switch studies: a review.Evaluation and management of dyslipidemia in patients with HIV infection.When to start antiretroviral therapy: the need for an evidence base during early HIV infectionSwitching effective antiretroviral therapy: a review.A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN TrialAntiretroviral therapies associated with lipoatrophy in HIV-infected womenPrevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in NigeriaFat distribution in women with HIV infection.Fat distribution in men with HIV infection.Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factorsRelation of body composition to body mass index in HIV-infected patients with metabolic abnormalitiesNew and emerging agents in the management of lipodystrophy in HIV-infected patients.Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).HIV revisited: the global impact of the HIV/AIDS epidemic.HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue.Mitochondrial toxicities of nucleoside analogue reverse transcriptase inhibitors in AIDS cases.HIV-associated lipodystrophy syndrome: A review of clinical aspects.Does mitochondrial dysfunction during antiretroviral therapy in human immunodeficiency virus infection suggest antioxidant supplementation as a beneficial option?Are HIV positive patients resistant to statin therapy?
P2860
Q24617882-BC5DB499-2069-47C4-8648-580A095FC410Q28366603-15BE63B8-5C55-47C9-893E-F0E7BB8E4C8AQ28775900-B624BE9F-C58D-4A62-8A40-2E05A39F24E0Q31055878-BE7A832F-E785-4401-860F-8FD8C78AE2ACQ33616201-7F0A8309-7C42-429D-927D-555D4887EE74Q33747646-CAB77564-3BEF-4644-9AE3-9A529E870B08Q33751516-3E71A970-170D-44A9-9D36-2B50594F3C71Q33804247-F8C9C9FA-C3CA-4475-ABD8-0694162D16D9Q33831138-19D320ED-216F-4E11-A7A3-9A4004E40D66Q33946920-62351E73-B3B2-4CF8-A499-339DC75864F0Q34052597-3890AC60-10E1-48F7-83B2-D3CB9DC02D2CQ34092346-49E86A66-EF2B-4CB8-865A-1CBB8BDBF116Q34187120-926DF0EA-D6D7-4B76-ABBB-80D6714C9D36Q34191314-E2951590-1503-40C3-8CD3-AD6D893E763FQ34282667-990B9AE2-4B3D-40A5-A57F-8DB09F1BB351Q34335535-8EDA1C65-FF43-4B9C-8204-F11F2034B190Q34459416-1E42781E-6CB1-4C31-A803-2927E5BFCAC5Q34464649-004950A6-01A8-4C85-AEAD-8EA60A4BAB5BQ34564488-61C637EB-E512-47B6-8D78-C881FFF0D0F7Q34631672-26FF53D4-7D7F-4F16-8B1E-A163C3799BB9Q34636824-916457B3-D644-4C24-A913-018838DAE5B2Q34743413-9567889C-5F68-47B3-9D8C-4BFA2EB208E0Q34773308-E4370DF2-3C26-4BFB-9BD2-6C944AB22E19Q34985833-96F88673-A3DE-4771-A6FE-AFA24EEAA7C4Q35012981-94B8B8BF-2276-44FC-8049-E04BDD2F7791Q35097650-BAA6C830-4882-472D-8426-8575A75E4275Q35187774-7A3FF44E-0AE7-493A-96C6-4F24F0CB85D8Q35194384-8F36D773-2FCD-43CB-BA02-FAA5C439EED2Q35194387-6FF96828-F642-4D5B-B7F0-E57D61E4879EQ35195035-9731D219-9190-47BC-BBA0-FB9215415592Q35206635-3D3DC5ED-969A-4024-9DC4-1CF88142D067Q35369261-596B3B1C-52E2-4385-90F9-ABAD849408D5Q35557229-17CB2AEA-AACE-484C-9811-7BAC866E73BEQ35637346-6152B36A-EDFC-49EA-857D-E24D1E915177Q35767480-8CB4CE41-DC0F-4453-870B-C10A5A625BEAQ35975980-FA2870C9-AB6E-4AAC-A946-DF2CDD141C87Q36008571-F9AB597E-240D-4831-9D7C-EF1D861DC897Q36171069-9F4606A8-1EEC-422D-8B4F-E44C3501B4D1Q36255314-1A0E9B54-ECFE-4868-850E-12ED82694AABQ36345121-AD1A2E86-D34A-4CDF-96FA-9407DB64983F
P2860
A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
A syndrome of peripheral fat w ...... m nucleoside analogue therapy.
@en
A syndrome of peripheral fat wasting
@nl
type
label
A syndrome of peripheral fat w ...... m nucleoside analogue therapy.
@en
A syndrome of peripheral fat wasting
@nl
prefLabel
A syndrome of peripheral fat w ...... m nucleoside analogue therapy.
@en
A syndrome of peripheral fat wasting
@nl
P2093
P1433
P1476
A syndrome of peripheral fat w ...... m nucleoside analogue therapy.
@en
P2093
Gastaut JA
Partisani M
Poizot-Martin I
Saint-Marc T
Touraine JL
P304
P356
10.1097/00002030-199909100-00009
P407
P577
1999-09-01T00:00:00Z